Hepatitis C and Its Impact on Renal Transplantation

Overview

Journal Nat Rev Nephrol

Specialty Nephrology

Date 2015 Feb 4

PMID 25643666

Citations 41

Authors

Jose M Morales

Fabrizio Fabrizi

Affiliations

Soon will be listed here.

Abstract

Infection with hepatitis C virus (HCV) is the major cause of chronic liver disease that occurs after renal transplantation. Such infection is often acquired during dialysis while patients wait to undergo renal transplantation. Renal transplantation is considered the best treatment option for patients with HCV infection and end-stage renal disease, although acceptance of a kidney graft by the host immune system and patient survival are lower compared to patients who test negative for HCV. The approval of interferon-free therapies could substantially change the natural history of HCV infection after renal transplantation. This Review discusses the interplay between renal transplantation, HCV infection, and liver disease. We emphasize the development of novel therapeutic strategies, including use of the newly identified direct-acting antiviral agents for treating hepatitis C among infected patients. We next analyse the most common clinical complications subsequent to HCV infection and the impact on graft and patient survival. Finally, we evaluate the consequences of kidney transplantation from HCV-positive donors.

Citing Articles

Efficacy of Direct Acting Antivirals (DAA) therapy in patients with recurrent hepatitis C after liver and kidney transplantation: a cross-sectional study.

Kashani M, Karimi M, Sharifi Rayeni A, Azizi Nadian M, Mortezazadeh M, Parsaei A Front Med (Lausanne). 2024; 11:1460372.

PMID: 39444819 PMC: 11496299. DOI: 10.3389/fmed.2024.1460372.

Renal Manifestations of Chronic Hepatitis C: A Review.

Sohal A, Singh C, Bhalla A, Kalsi H, Roytman M J Clin Med. 2024; 13(18).

PMID: 39337023 PMC: 11433393. DOI: 10.3390/jcm13185536.

Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study.

Artan A, Mirioglu S, Istemihan Z, Aksoy E, Dirim A, Cavus B Balkan Med J. 2023; 40(3):182-187.

PMID: 36960943 PMC: 10175878. DOI: 10.4274/balkanmedj.galenos.2023.2022-10-13.

Analysis of the effects of donor and recipient hepatitis C infection on kidney transplant outcomes in the United States.

Yuan Q, Hong S, Leya G, Roth E, Tsoulfas G, Williams W World J Transplant. 2023; 13(2):44-57.

PMID: 36908306 PMC: 9993188. DOI: 10.5500/wjt.v13.i2.44.

Virus-Associated Nephropathies: A Narrative Review.

Masset C, Le Turnier P, Bressollette-Bodin C, Renaudin K, Raffi F, Dantal J Int J Mol Sci. 2022; 23(19).

PMID: 36233315 PMC: 9569621. DOI: 10.3390/ijms231912014.

References

Manuel O, Baid-Agrawal S, Moradpour D, Pascual M . Immunosuppression in hepatitis C virus-infected patients after kidney transplantation. Contrib Nephrol. 2012; 176:97-107. DOI: 10.1159/000332387. View

Goodkin D, Bieber B, Gillespie B, Robinson B, Jadoul M . Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013; 38(5):405-12. DOI: 10.1159/000355615. View

Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C . Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1998; 29(1):257-63. DOI: 10.1002/hep.510290123. View

Toz H, Nart D, Turan I, Ersoz G, Sezis M, Asci G . The acquisition time of infection: a determinant of the severity of hepatitis C virus-related liver disease in renal transplant patients. Clin Transplant. 2009; 23(5):723-31. DOI: 10.1111/j.1399-0012.2009.01017.x. View

Lens S, Gambato M, Londono M, Forns X . Interferon-free regimens in the liver-transplant setting. Semin Liver Dis. 2014; 34(1):58-71. DOI: 10.1055/s-0034-1371011. View

Vosnides G . Hepatitis C in renal transplantation. Kidney Int. 1997; 52(3):843-61. DOI: 10.1038/ki.1997.403. View

Maluf D, Archer K, Mas V . Kidney grafts from HCV-positive donors: advantages and disadvantages. Transplant Proc. 2010; 42(7):2436-46. DOI: 10.1016/j.transproceed.2010.04.056. View

Morales J, Campistol J, Andres A, Rodicio J . Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens. 1998; 6(6):511-5. DOI: 10.1097/00041552-199711000-00001. View

Izopet J, Rostaing L, Sandres K, Cisterne J, Pasquier C, RUMEAU J . Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis. 2000; 181(3):852-8. DOI: 10.1086/315355. View

10.

Lun Yau A, Yoshida E . Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol. 2014; 28(8):445-51. PMC: 4210236. DOI: 10.1155/2014/549624. View

11.

Cruzado J, Gil-Vernet S, Ercilla G, Seron D, Carrera M, Bas J . Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol. 1996; 7(11):2469-75. DOI: 10.1681/ASN.V7112469. View

12.

Kamar N, Rostaing L, Selves J, Sandres-Saune K, Alric L, Durand D . Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant. 2005; 5(7):1704-12. DOI: 10.1111/j.1600-6143.2005.00918.x. View

13.

Kliem V, Burg M, Haller H, Suwelack B, Abendroth D, Fritsche L . Relationship of hepatitis B or C virus prevalences, risk factors, and outcomes in renal transplant recipients: analysis of German data. Transplant Proc. 2008; 40(4):909-14. DOI: 10.1016/j.transproceed.2008.03.031. View

14.

Bucci J, Lentine K, Agodoa L, Peters T, Schnitzler M, Abbott K . Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS/UNOS database. Clin Transpl. 2006; :51-61. View

15.

Gentil M, Rocha J, Rodriguez-Algarra G, Pereira P, Lopez R, Bernal G . Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant. 1999; 14(10):2455-60. DOI: 10.1093/ndt/14.10.2455. View

16.

Morales J, Campistol J, Castellano G, Andres A, Colina F, Fuertes A . Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int. 1995; 47(1):236-40. DOI: 10.1038/ki.1995.29. View

17.

Schmitz V, Kiessling A, Bahra M, Puhl G, Kahl A, Berg T . Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant. 2008; 12(3):22-7. View

18.

Kucirka L, Singer A, Ros R, Montgomery R, Dagher N, Segev D . Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010; 10(5):1238-46. DOI: 10.1111/j.1600-6143.2010.03091.x. View

19.

Baid S, Pascual M, Williams Jr W, Tolkoff-Rubin N, Johnson S, Collins B . Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol. 1999; 10(1):146-53. DOI: 10.1681/ASN.V101146. View

20.

Pageaux G, Hilleret M, Garrigues V, Bismuth M, Audin-Mamlouk H, Zarski J . Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transpl Int. 2009; 22(5):562-7. DOI: 10.1111/j.1432-2277.2008.00831.x. View